1 / 7

Outpatient Antibiotic Use in Europe and Association with Resistance.

The LANCET Volume 365, Number 9459 12 February 2005. Outpatient Antibiotic Use in Europe and Association with Resistance. Herman Goossens, M.D., Ph.D., Matus Ferech, Pharm.D., Robert Vander Stichele, M.D., , Monique Elseviers, Ph.D, and the ESAC Project Group.

myrna
Download Presentation

Outpatient Antibiotic Use in Europe and Association with Resistance.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The LANCET Volume 365, Number 9459 12 February 2005 Outpatient Antibiotic Use in Europe and Association with Resistance. Herman Goossens, M.D., Ph.D., Matus Ferech, Pharm.D., Robert Vander Stichele, M.D., , Monique Elseviers, Ph.D, and the ESAC Project Group. From the ESAC Management Team, Department of Microbiology, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium Address for correspondence: Prof. Dr. H. Goossens Department of Microbiology, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium Tel (+) 32 3 821 3789 Fax (+) 32 3 825 4281 E-mail: Herman.Goossens@uza.be

  2. Figure 1 Total Outpatient antibiotic use in 26 European countries in 2002

  3. Figure 2 Seasonal variation of total outpatient antibiotic use in 10 European countries

  4. Figure 3 Outpatient use of penicillins (J01C) in 26 European countries in 2002 in descending order of narrow spectrum penicillins

  5. Figure 5 Outpatient use of the third generation Cephalosporins in 2002

  6. Figure 6 Outpatient use of Macrolides, Lincosamides and Streptogramins (J01F) in 26 European countries in 2002

  7. Figure 7 Outpatient use of Quinolones (J01M) in 26 European countries in 2002

More Related